Poseida Therapeutics, Inc. (NASDAQ: PSTX) reported Q2 EPS of ($0.32), $0.21 better than the analyst estimate of ($0.53). Revenue for the quarter came in at $20.01 million versus the consensus estimate of $11.96 million.

For earnings history and earnings-related data on Poseida Therapeutics, Inc. (PSTX) click here.